


MEDICAL POLICY – 2.01.536

Noninvasive Tests for Hepatic Fibrosis

Ref. Policy: PA-101		RELATED MEDICAL POLICIES: None
Effective Date:	Jan. 1, 2024	
Last Revised:	Mar. 1, 2024	
Replaces:	N/A	

Select a hyperlink below to be directed to that section.

- [POLICY CRITERIA](#) | [CODING](#) | [RELATED INFORMATION](#)
- [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

Introduction

Liver fibrosis is a process where healthy liver tissue is replaced by scar tissue from repeated injury or inflammation. It can be caused by diseases like hepatitis. The scar tissue causes stiffness in the liver and can lead to more serious liver disease. Certain noninvasive tests can be used to detect and monitor liver fibrosis. These include blood tests and imaging studies that use ultrasound and magnetic resonance imaging. This policy describes when noninvasive testing for liver fibrosis may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Service	Medical Necessity
Enhanced Liver Fibrosis (ELF) Test	Enhanced Liver Fibrosis (ELF) Test and Fibro Test (FT) - Acti Test/HCV - Fibrosure may be considered medically necessary

Service	Medical Necessity
<p>Fibro Test (FT) - Acti Test/HCV- Fibrosure</p>	<p>for the detection and prognosis of liver fibrosis in persons with chronic liver diseases when the following criteria are met:</p> <ul style="list-style-type: none"> • To evaluate hepatic fibrosis in chronic hepatitis C individuals <p>OR</p> <ul style="list-style-type: none"> • To diagnose fibrosis in carriers of chronic hepatitis B virus <p>OR</p> <ul style="list-style-type: none"> • To evaluate hepatic fibrosis in co-infected HIV carriers <p>OR</p> <ul style="list-style-type: none"> • To provide access to new-generation non-interferon treatment for hepatitis <p>OR</p> <ul style="list-style-type: none"> • To evaluate fibrosis in individuals suffering from metabolic conditions (non-alcoholic fatty liver disease) and individuals who consume excess alcohol <p>Performance of Fibro Test (FT) - Acti Test/HCV- Fibrosure test more than twice per year or within 6 months following a liver biopsy or transient elastography is considered not medically necessary.</p> <ul style="list-style-type: none"> • The advice of a liver disease specialist should be sought for interpretation in chronic states in which the components of the test could be modified, such as chronic hemolysis, particularly in individuals with a cardiac valvular prosthesis; Gilbert disease; protease inhibitors used in HIV treatment, which can increase unconjugated bilirubin (Indinavir, Atazanavir); or gamma glutamyltransferase (GGT) and alanine aminotransferase (Ritonavir). <p>Fibro Test (FT) - Acti Test/HCV- Fibrosure is considered investigational for all other indications.</p> <p>Note: See Related Information below for Limitations</p>
<p>Magnetic Resonance Elastography</p>	<p>Magnetic resonance elastography may be considered medically necessary for non-alcoholic steatohepatitis (NASH), and hepatic fibrosis or cirrhosis is known or suspected.</p>



Service	Medical Necessity
	<p>Magnetic resonance elastography is investigational for:</p> <ul style="list-style-type: none"> • Distinguishing hepatic cirrhosis from non-cirrhosis in persons with hepatitis C or other chronic liver diseases • All other indications (e.g., prediction of ascites in persons with chronic liver disease)
<p>Transient Elastography (TE) (e.g., FibroScan)</p>	<p>Transient Elastography (TE) (e.g., FibroScan) may be considered medically necessary for the following indications:</p> <ul style="list-style-type: none"> • Initial assessment of fibrosis of individuals with a diagnosis with hepatitis C <p>OR</p> <ul style="list-style-type: none"> • Follow-up assessment of fibrosis of individuals with a diagnosis of hepatitis C and previously documented F0, F1, or F2 per METAVIR staging guidelines <p>OR</p> <ul style="list-style-type: none"> • Assessment of advanced fibrosis (F2 or greater) versus minimal or no fibrosis (F1 or F0) <p>TE (e.g., FibroScan) is considered not medically necessary when any of the following is present:</p> <ul style="list-style-type: none"> • The individual has a BMI of <19 kg/m² or >30 kg/m² • Ascites • Focal lesions within the liver (e.g., tumor) • Acute liver injury • Previously documented liver fibrosis of F3 or F4 • The individual is pregnant • Alanine transaminase (ALT) level five or more times the upper limit of normal (55 units per liter) • Implanted metal device (e.g., pacemaker, automated implantable cardioverter defibrillator (AICD), or any other implantable defibrillators) • TE performed within the previous 12 months • Liver biopsy performed within the previous six months <p>TE is considered investigational for all other indications.</p>



Service	Investigational
Detection or monitoring of hepatic fibrosis in persons with hepatitis C or other chronic liver diseases	<p>The following are considered investigational for the detection or monitoring of hepatic fibrosis in persons with hepatitis C or other chronic liver diseases (e.g., NAFLD) (not an all- inclusive list):</p> <ul style="list-style-type: none"> • Acoustic Radiation Forced Impulse (ARFI) • Hepatic Artery Resistive Index • Serum Marker Tests including: <ul style="list-style-type: none"> ○ Angiotensin converting enzyme ○ FibroMAX ○ FibroSpect ○ HepaScore ○ LIVERFAST ○ Micro-fibrillar associated glycoprotein 4 (MFAP4) ○ MicroRNA-21 ○ miR-29a and miR-122 ○ miRNA-221 and miRNA-222 ○ NASH FibroSure ○ Plasma cytokeratin-18 ○ Signal-induced proliferation associated 1 like 1 (SIPA1L1)

Coding

Code	Description
CPT	
0014M	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years (ELF) (code termed 1/1/2024)
76981	Ultrasound, elastography; parenchyma (e.g., organ)
76982	Ultrasound, elastography; first target lesion
76983	Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)



Code	Description
81517	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years
81596	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver (Fibro Test (FT) - Acti Test/HCV- Fibrosure)
91200	Liver elastography, mechanically induced shear wave (e.g., vibration), without imaging, with interpretation and report

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Tests

- Enhanced Liver Fibrosis (ELF) Test: measures three direct markers of fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1)
- Fibro Test (FT) - Acti Test/HCV- Fibrosure: consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin, plus alanine aminotransferase)

Limitations – FibroTest-ActiTest

Detection and prognosis of liver fibrosis in persons with chronic liver diseases:

Defer the test in transient situations that could modify the components of FibroTest-ActiTest, such as:

- Acute hemolysis, which could decrease haptoglobin and increase unconjugated bilirubin



- Acute hepatitis, whether drug-induced, viral (superinfection by hepatitis A virus: HAV, hepatitis B virus: HBV, Epstein-Barr virus: EBV), or autoimmune. Massive hepatic necrosis leads to a large increase of transaminases and total bilirubin.
- Acute inflammation, as with concomitant bacterial or acute viral infection: bronchopulmonary or urinary tract infection. The large increase of haptoglobin can lead to false-negative results.
- Extrahepatic cholestasis, such as gallstones

Transient elastography (TE):

METAVIR Scoring System	
Activity Grade	
A0	No activity
A1	Mild activity
A2	Moderate activity
A3	Severe activity
Fibrosis Stage	
F0	No fibrosis
F1	Fibrous portal expansion (mild fibrosis)
F2	Few bridges or septa (moderate fibrosis)
F3	Numerous bridges or septa (severe fibrosis)
F4	Cirrhosis

Evidence Review

Background

Fibrosis and inflammatory activity are the two main causes of liver disease.



FibroTest-ActiTest estimates the levels of fibrosis and cirrhosis in the liver as well as the level of necroinflammatory activity. The estimation is made by measuring five fibrosis markers (gamma-glutamyl transferase, total bilirubin, alpha-2-macroglobulin, apolipoprotein A1, haptoglobin, plus alanine aminotransferase). The activity score is a measure of liver inflammation caused by disease. Results from these tests are combined with the individual's age and sex to estimate hepatic fibrosis and inflammatory activity scores.

Hepatic fibrosis is typically compared to a form of scar tissue that progresses throughout the liver. The most serious stage of fibrosis is known as cirrhosis.

Fibrosis is a scarring process that replaces damaged liver cells, causing inflammation and leading to the formation of fibrous scar tissue in the liver. Transient Elastography (TE) is a non-invasive technique for the evaluation of fibrosis in chronic liver disease. TE serves as an alternative to liver biopsy, the gold standard for evaluating liver fibrosis. TE measures liver stiffness by tracking the wave speed through ultrasound.

The only system suitable for performing TE is the FibroScan System (Echosens SA; Paris, France), as approved by the US Food and Drug Administration (FDA) on April 5, 2013.

References

1. BioPredictive: Technical Recommendations for FibroTest and FibroMax assays, Bio Predictive. <https://www.biopredictive.com/products/fibromax/>. Accessed November 21, 2023.
2. Halfon P, Bourliere M, Deydier R, et al: Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. *Am J Gastroenterol*. 2006 Mar;101(3):547-555. doi: 10.1111/j.1572-0241.2006.00411.x. <https://pubmed.ncbi.nlm.nih.gov/16542291/>. Accessed November 21, 2023.
3. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T: Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. *Aliment Pharmacol Thera*. 2016 Jan;43:16-29. doi: 10.1111/apt.13446. <https://pubmed.ncbi.nlm.nih.gov/26516104/>. Accessed November 21, 2023.
4. Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-Lyon I, Williams R: Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. *Eur J Gastroenterol Hepatol*. 2010 Apr;22(4):474-480. doi: 10.1097/MEG.0b013e328332dd0a. <https://pubmed.ncbi.nlm.nih.gov/19887952/>. Accessed November 21, 2023.
5. Martínez SM, Crespo G, Navasa M, Forns X: Noninvasive assessment of liver fibrosis. *Hepatology*. 2011 Jan;53(1):325-335. doi: 10.1002/hep.24013. <https://pubmed.ncbi.nlm.nih.gov/21254180/>. Accessed November 21, 2023.
6. Afdahl NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. *Gastroenterol Hepatol (NY)*. 2012 Sep;8(9):605-607. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594956/>. Accessed November 21, 2023.



7. Castera L, Foucher L, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. *Hepatology*. 2010 Mar;51(3):828-835. doi: 10.1002/hep.23425. <http://onlinelibrary.wiley.com/doi/10.1002/hep.23425/full>. Accessed November 21, 2023.
8. Crespo G, Fernandez-Varo G, Marino Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. *J Hepatol*. 2012 Aug;57(2):281-287. doi: 10.1016/j.jhep.2012.03.016. Epub 2012 Apr 17. <http://www.sciencedirect.com/science/article/pii/S0168827812002711>. Accessed November 21, 2023.
9. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). *J Hepatol*. 2010 Dec;53(6):1013-1021. doi: 10.1016/j.jhep.2010.05.035. Epub 2010 Aug 14. <http://www.sciencedirect.com/science/article/pii/S0168827810006926>. Accessed November 21, 2023.
10. Foucher J, Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut*. 2006 Mar;55(3):403-408. Epub 2005 Jul 14. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856085/>. Accessed November 21, 2023.
11. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology*. 2008 Apr;134(4):960-974. doi: 10.1053/j.gastro.2008.01.034. Epub 2008 Jan 18. <http://www.sciencedirect.com/science/article/pii/S001650850800108X>. Accessed November 21, 2023.
12. Hayes Medical Technology Directory. Ultrasound Transient Elastography for Detecting Hepatic Fibrosis in Patients with Hepatitis C. Publication Date: March 27, 2019. Accessed November 21, 2023.
13. HepatitisCentral.com. Table 4. The METAVIR System. Algorithm for Evaluation of Histological Activity. Copyright ©1994-2019 Hepatitis Central. Available at: <http://www.hepatitiscentral.com/hcv/biopsy/charts/metavir.html>. Accessed November 21, 2023.
14. Kemp W, Roberts S. FibroScan and transient elastography. *Aust Fam Physician*. 2013 Jul;42(7):468-471. <http://www.racgp.org.au/afp/2013/july/fibroscan/>. Accessed November 21, 2023.
15. U.S. Food and Drug Administration (FDA). Echosens' FibroScan System. 510(k) Summary. K123806. Approved: Apr. 5, 2013. (Manufacturer: Echosens SA). https://www.accessdata.fda.gov/cdrh_docs/pdf12/k123806.pdf. Accessed November 21, 2023.
16. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). *Gastroenterol Rep (Oxf)*. 2013 Jul;1(1):19-26. doi: 10.1093/gastro/got007. Epub 2013 Mar 26. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941434/>. Accessed November 21, 2023.
17. Zachary D, Goodman. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. *Journal of Hepatology* 47 (2007) 598–607. <https://pubmed.ncbi.nlm.nih.gov/17692984/>. Accessed November 21, 2023.
18. Yasaman Vali, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology* 2020 vol. 73 j 252–262. <https://pubmed.ncbi.nlm.nih.gov/32275982/>. Accessed November 21, 2023.

History

Date	Comments
09/16/19	New policy, approved August 13, 2019, effective January 1, 2020. Transient Elastography (TE) (e.g., FibroScan) may be considered medically necessary for the indications listed in this policy; otherwise, considered investigational.



Date	Comments
11/01/20	Annual Review, approved October 22, 2020. No changes to policy statement, references updated.
05/01/21	Annual Review, approved April 1, 2021. No changes to policy statement, references updated. Added CPT codes 76981, 76982 and 76983.
02/01/22	Annual Review, approved January 24, 2022. Title changed from "Transient Elastography" to "Noninvasive Tests for Hepatic Fibrosis". Added Medically Necessary criteria for non-invasive blood tests: considered medically necessary for the detection and prognosis of liver fibrosis in persons with chronic liver diseases and criteria for Magnetic Resonance Elastography. References updated. Added CPT codes 0014M and 81596.
01/01/23	Interim Review, approved December 12, 2022. No changes to policy statement, references updated. Changed the wording from "patient" to "individual" throughout the policy for standardization.
01/01/24	Annual Review, approved December 11, 2023. Formatting changes made to policy statement table to clarify that criteria applies to both the Enhanced Liver Fibrosis (ELF) Test and the Fibro Test (FT) - Acti Test/HCV – Fibrosure; policy statements unchanged.
03/01/24	Coding update. Removed termed code 0014M and added CPT code 81517.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2024 Premera All Rights Reserved.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy only applies to Individual Plans.



Discrimination is Against the Law

Premera Blue Cross (Premera) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). Premera provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator — Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-4535, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@Premera.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Washington residents: You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at <https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status>, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at <https://fortress.wa.gov/oic/online-services/cc/pub/complaintinformation.aspx>.

Alaska residents: Contact the Alaska Division of Insurance via email at insurance@alaska.gov, or by phone at 907-269-7900 or 1-800-INSURAK (in-state, outside Anchorage).

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-607-0546 (TTY: 711).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-607-0546 (TTY: 711).

注意: 如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-607-0546 (TTY: 711)。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-607-0546 (TTY: 711).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-607-0546 (TTY: 711) 번으로 전화해 주십시오.

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-607-0546 (телетайп: 711).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 800-607-0546 (TTY: 711).

MO LOU SILAFIA: Afai e te tautala Gagana fa'a Sāmoa, o loo iai auunaga fesoasoan, e fai fua e leai se totagi, mo oe, Telefoni mai: 800-607-0546 (TTY: 711).

ໂປດອຸລາ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ຄ່າສ່ຽງຄ່າ, ຄມມນມິພ້ອມໃຫ້ທ່ານ. ໂທ 800-607-0546 (TTY: 711).

注意事項: 日本語を話される場合、無料の言語支援をご利用いただけます。800-607-0546 (TTY:711) まで、お電話にてご連絡ください。

PAKDAAR: Nu saritaem ti Ilocano, ti serbisyo para ti baddang ti lengguahe nga awanan bayadna, ket sidadaan para kenyam. Awagan ti 800-607-0546 (TTY: 711).

УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки. Телефонуйте за номером 800-607-0546 (телетайп: 711).

ប្រយ័ត្ន: បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតលុយ គឺអាចមានសំរាប់អ្នក។ ចូរ ទូរស័ព្ទ 800-607-0546 (TTY: 711)។

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም አርዳታ ድርጅቶች: በነጻ ሊያግዝዎት ተዘጋጅተዋል: ወደ ሚከተለው ቁጥር ይደውሉ 800-607-0546 (መስማት ለተሳናቸው: 711).

XIYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajjila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-607-0546 (TTY: 711).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-607-0546 (رقم هاتف الصم والبكم: 711).

ਧਿਆਨ ਦਿਓ: ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-607-0546 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

ထိစား: ထိုကုမ္ပဏီကထာဝရစာအုပ်အားအားပေးရန်အတွက်အထောက်အကူပြုပေးမည်။ 800-607-0546 (TTY: 711)။

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-607-0546 (TTY: 711).

UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-607-0546 (TTY: 711).

ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 800-607-0546 (TTY: 711).

ATTENTION: Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-607-0546 (ATS: 711).

ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-607-0546 (TTY: 711).

ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-607-0546 (TTY: 711).

توجہ: اگر بہ زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-607-0546 (TTY: 711) تماس بگیرید.